ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 132 filers reported holding ENANTA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 1.88 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,028,265 | -84.5% | 450,158 | -70.4% | 0.00% | -100.0% |
| Q2 2023 | $32,490,571 | -33.1% | 1,518,251 | +26.4% | 0.00% | -33.3% |
| Q1 2023 | $48,565,852 | -65.5% | 1,200,936 | -60.3% | 0.00% | -25.0% |
| Q4 2022 | $140,694,344 | +96.9% | 3,024,384 | +119.6% | 0.00% | -20.0% |
| Q3 2022 | $71,447,000 | -11.1% | 1,377,417 | -18.9% | 0.01% | 0.0% |
| Q2 2022 | $80,332,000 | -13.8% | 1,699,428 | +29.9% | 0.01% | 0.0% |
| Q1 2022 | $93,145,000 | +10.5% | 1,308,586 | +16.1% | 0.01% | +25.0% |
| Q4 2021 | $84,282,000 | +38.4% | 1,127,069 | +5.1% | 0.00% | +33.3% |
| Q3 2021 | $60,911,000 | +31.3% | 1,072,182 | +1.7% | 0.00% | +50.0% |
| Q2 2021 | $46,390,000 | -14.3% | 1,054,075 | -4.0% | 0.00% | -33.3% |
| Q1 2021 | $54,159,000 | +9.6% | 1,098,124 | -6.4% | 0.00% | 0.0% |
| Q4 2020 | $49,393,000 | +12.0% | 1,173,240 | +21.8% | 0.00% | 0.0% |
| Q3 2020 | $44,110,000 | -17.1% | 963,518 | -9.0% | 0.00% | -25.0% |
| Q2 2020 | $53,177,000 | +13.9% | 1,059,096 | +16.7% | 0.00% | 0.0% |
| Q1 2020 | $46,695,000 | -9.0% | 907,924 | +9.3% | 0.00% | 0.0% |
| Q4 2019 | $51,330,000 | -3.2% | 830,853 | -5.9% | 0.00% | 0.0% |
| Q3 2019 | $53,053,000 | -26.9% | 883,036 | +2.6% | 0.00% | -20.0% |
| Q2 2019 | $72,597,000 | -17.4% | 860,358 | -6.5% | 0.01% | -28.6% |
| Q1 2019 | $87,922,000 | +29.2% | 920,453 | -4.2% | 0.01% | +16.7% |
| Q4 2018 | $68,073,000 | -33.6% | 961,079 | -19.9% | 0.01% | -25.0% |
| Q3 2018 | $102,479,000 | +14.8% | 1,199,167 | +55.7% | 0.01% | +14.3% |
| Q2 2018 | $89,281,000 | +45.6% | 770,299 | +1.6% | 0.01% | +40.0% |
| Q1 2018 | $61,309,000 | +44.7% | 757,799 | +5.0% | 0.01% | +66.7% |
| Q4 2017 | $42,360,000 | +25.6% | 721,896 | +0.1% | 0.00% | 0.0% |
| Q3 2017 | $33,738,000 | +36.7% | 720,999 | +5.1% | 0.00% | +50.0% |
| Q2 2017 | $24,686,000 | +7.0% | 686,047 | -8.4% | 0.00% | 0.0% |
| Q1 2017 | $23,063,000 | +21.2% | 748,824 | +31.8% | 0.00% | 0.0% |
| Q4 2016 | $19,036,000 | +115.9% | 568,238 | +71.5% | 0.00% | +100.0% |
| Q3 2016 | $8,818,000 | -38.7% | 331,367 | -49.2% | 0.00% | -50.0% |
| Q2 2016 | $14,382,000 | -15.8% | 652,261 | +12.2% | 0.00% | 0.0% |
| Q1 2016 | $17,081,000 | -11.5% | 581,552 | -0.5% | 0.00% | 0.0% |
| Q4 2015 | $19,305,000 | -40.4% | 584,560 | -34.7% | 0.00% | -50.0% |
| Q3 2015 | $32,365,000 | -14.7% | 895,613 | +6.2% | 0.00% | 0.0% |
| Q2 2015 | $37,926,000 | +59.1% | 843,110 | +8.3% | 0.00% | +100.0% |
| Q1 2015 | $23,836,000 | -10.1% | 778,528 | +49.2% | 0.00% | -33.3% |
| Q4 2014 | $26,528,000 | +437.5% | 521,774 | +318.4% | 0.00% | +200.0% |
| Q3 2014 | $4,935,000 | -6.7% | 124,697 | +1.5% | 0.00% | 0.0% |
| Q2 2014 | $5,288,000 | +161.0% | 122,797 | +142.5% | 0.00% | – |
| Q1 2014 | $2,026,000 | +73.6% | 50,644 | +18.3% | 0.00% | – |
| Q4 2013 | $1,167,000 | +49.0% | 42,800 | +25.2% | 0.00% | – |
| Q3 2013 | $783,000 | – | 34,197 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 476,042 | $45,472,000 | 12.29% |
| Stonepine Capital Management, LLC | 60,840 | $5,811,000 | 3.34% |
| ACUTA CAPITAL PARTNERS, LLC | 61,000 | $5,827,000 | 2.77% |
| Virtus ETF Advisers LLC | 10,634 | $1,016,000 | 2.16% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 61,000 | $5,827,000 | 2.15% |
| ARMISTICE CAPITAL, LLC | 372,000 | $35,533,000 | 1.94% |
| Matarin Capital Management, LLC | 209,403 | $20,002,000 | 1.46% |
| Monashee Investment Management LLC | 50,000 | $4,776,000 | 1.10% |
| Granahan Investment Management | 151,322 | $14,454,000 | 0.78% |
| ALGERT GLOBAL LLC | 13,186 | $1,260,000 | 0.72% |